)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
BioInvent International (BINV) investor relations material
BioInvent International Jefferies London Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Jefferies London Healthcare Conference 2025 summary18 Nov, 2025
Company overview, platform, and technology
Integrated operations and the F.I.R.S.T. platform enable rapid discovery and development of novel immuno-oncology therapies, with in-house GMP manufacturing and licensing opportunities.
Strategic partnerships with major pharma companies, including Merck and AstraZeneca, support clinical development, validation, and deal-making.
Strong international shareholder base, with a financial runway into Q1 2027 and a cash position of SEK 690M (~$73M) as of September 30, 2025.
Fast Track and Orphan Drug Designations granted for both lead clinical programs, supporting regulatory pathways.
Clinical development, pipeline, and data highlights
BI-1808 (anti-TNFR2) and BI-1206 (anti-FcγRIIB) are the main clinical-stage assets, both in multiple Phase 2 studies for lymphoma and solid tumors, with data readouts expected in H2 2025 and H1 2026.
BI-1808 shows exceptional safety and efficacy in CTCL and solid tumors, with over 40% response rate in CTCL and 100% DCR in initial Phase 2a CTCL data.
BI-1206 demonstrates strong efficacy and safety in NHL, with 59% ORR and 41% CRR in relapsed/refractory FL patients, and 100% DCR in triple combination with rituximab and acalabrutinib.
Both assets are being tested as single agents and in combination with pembrolizumab or other partner drugs, with combination data expected by year-end and further data in H2 2025 and H2 2026.
Subcutaneous formulation of BI-1206 offers convenience and safety, with no cytokine release syndrome or neurotoxicity observed.
Commercial strategy, market positioning, and future plans
Initial focus on quick-to-market opportunities in second-line settings (CTCL for BI-1808, follicular lymphoma for BI-1206), with expansion to first-line and larger solid tumor indications.
Market opportunities include $500 million for second-line follicular lymphoma and significant potential in ovarian and lung cancers.
Ongoing and upcoming data releases at major conferences (ASH, EHA) and key readouts expected by end of 2024, mid-2025, and H2 2026.
Plans to initiate pivotal Phase 2 and confirmatory Phase 3 studies for both assets in 2026–2027, with potential BLA submission and approval timelines from 2026 onward.
Broad mechanism of action allows for potential expansion into additional cancer indications beyond current focus.
BI-1206 safety vs. 3rd line CAR-T/bispecifics?
Rationale for heme ONC quick-to-market strategy
How does FIRST platform ensure future pipeline?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next BioInvent International earnings date
Q4 202527 Feb, 2026
Next BioInvent International earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage